CancerNetwork Members: Login | Register
 

 
MULTIMEDIA
IMAGES
Chronic myeloid leukemia (CML): marked leucocytosis with granulocyte left shift. Source: Paulo Mourao, Wikimedia Commons


Microscopic analysis of blood smear stained with May-Grünwald/Giemsa, from a patient with Chronic Myeloid Leukemia. Source: Dr Ramon Simon-Lopez, Wikimedia Commons

VIDEOS
Dr. Sonali Smith discusses the newest developments in the treatment of CML.


Dr. Jorge Cortes discusses new data on bosutinib, a new tyrosine kinase inhibitor for CML.
 

 
NEWS
Medical News: ASH: Major Studies on Tap for 2011 Meeting - in Meeting Coverage, ASH: Hematology from MedPage Today
www.medpagetoday.com -
 
JOB LISTINGS

Post a job

Powered by SearchMedica Jobs
 
CONNECT WITH US
Become a fan on
Facebook
Add us on
Google Plus
Follow us on
Twitter
Sign up for our
Newsletters
Subscribe to our
RSS Feed

Chronic Myeloid Leukemia
 
FEATURED CONTENT
February 6, 2012
FDA Grants Imatinib (Gleevec) Full Approval for Adjuvant Treatment of GIST
The FDA has granted imatinib full approval as an adjuvant treatment following surgical removal of CD117-positive gastrointestinal stromal tumors in adult patients. This comes after results from a... More »
January 17, 2012
What to Order From the Prostate Cancer Treatment Menu?
These are, indeed, exciting times for patients with metastatic prostate cancer and the clinicians who care for them. More »
January 13, 2012
Continuing Good News for Chronic Myeloid Leukemia Patients
The results of the 2-year follow-up of the dasatinib DASISION phase III trial show the continued superiority of the drug compared to imatinib. The results provide further support for treatment of... More »
December 31, 2011
Acute Leukemias
Hematopoietic malignancies account for 6% to 8% of new cancers diagnosed annually. In the year 2010, an estimated 43,050 new cases of leukemia were diagnosed, and 21,840 deaths were attributable to... More »
December 20, 2011
Fluid Complications
Malignant pleural effusion complicates the care of approximately 150,000 people in the United States each year. More »
November 30, 2011
Hematopoietic Cell Transplantation
Hematopoietic cell transplantation (HCT) is the IV infusion of hematopoietic stem and progenitor cells designed to establish marrow and immune function in patients with a variety of acquired and... More »
November 10, 2011
Chronic Myeloid Leukemia
Chronic myeloid leukemia (CML) is a clonal myeloproliferative disorder resulting from the neoplastic transformation of the primitive hematopoietic stem cell. More »
November 10, 2011
Myelodysplastic Syndromes
Myelodysplastic syndromes (MDS) are a group of hematologic malignancies of the pluripotent hematopoietic stem cells. These disorders are characterized by ineffective hematopoiesis, including... More »
October 12, 2011
Mucocutaneous Paraneoplastic Syndromes Associated With Hematologic Malignancies
Paraneoplastic pemphigus (PNP) is an autoimmune-mediated, blistering, erosive, and painful mucocutaneous disease that is diagnosed almost exclusively in patients with lymphocytic neoplasms. More »
August 19, 2011
63-year-old Male Hospitalized Following a Massive Hemorrhage
A 63-year-old male was hospitalized following a massive hemorrhage secondary to a motor vehicle accident and subsequent infection of a surgical site. Three weeks post-admittance his WBC demonstrated a... More »
Showing 1 - 10 of 122 results.
Page of 13
First Previous Last
 
JOURNAL SCAN
Oncogene - MicroRNA-335 acts as a metastasis suppressor in gastric cancer by targeting Bcl-w and specificity protein 1
www.nature.com - 8/8/11
Oncogene is one of the worlds leading cancer journals. It is published weekly and covers all aspects of the structure and function of Oncogenes.
Breast Cancer Research | Full text | What's new on Circulating Tumor Cells? A meeting report
breast-cancer-research.com - 7/23/10
Circulating tumor cells (CTCs) provide unique information for the management of cancer patients. The 7th International Symposium on Minimal Residual Cancer has focused on state of the art research, including exciting advances in understanding the biology of metastasis, CTCs and tumor dormancy. Particular emphasis was placed on the relationship of CTCs to cancer stem cells (CSCs) and the relevance of most recent findings for the development of new targeted therapies. CTCs were evaluated as promising tumor
Genome Medicine | Full text | ABO blood group and other genetic variants associated with pancreatic cancer
genomemedicine.com - 6/22/10
Pancreatic adenocarcinoma is the fourth leading cause of cancer death in the United States. Recent reports, including genome-wide association studies and self-reported blood serotype studies, have shown that individuals of European ancestry who carry non-O blood group are at an increased risk of developing pancreatic cancer. Two recent genome-wide association studies of pancreatic cancer have identified associations between pancreatic cancer risk and genetic variants in the ABO blood group gene, the locus
Cancer Cell International | Full text | Decreased therapeutic effects of noscapine combined with imatinib mesylate on human glioblastoma in vitro and the effect of midkine
www.cancerci.com - 6/8/11
Glioblastoma (GBM) develops resistance to the advances in chemotherapy leading to poor prognosis and life quality. Consequently, new treatment modalities are needed. Our aims were to investigate the effects of combined noscapine (NOS) and imatinib mesylate (IM) on human GBM in vitro and the role of midkine (MK) in this new combination treatment.|Glioblastoma (GBM) develops resistance to the advances in chemotherapy leading to poor prognosis and life quality. Consequently, new treatment modalities are neede
Oncogene - GILZ inhibits the mTORC2/AKT pathway in BCR-ABL+ cells
www.nature.com - 8/1/11
Oncogene is one of the worlds leading cancer journals. It is published weekly and covers all aspects of the structure and function of Oncogenes.

Result Pages: 1 2 3 4 5 6 Previous Next


 
CLINICAL TRIALS
An Open-Label, Multicenter, Expanded Access Study of Oral AMN 107 in Adult Patients With Imatinib (Glivec/Gleevec_ - Resistant or Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase - Full Text View - ClinicalTrials.
www.clinicaltrials.gov -
Immunotherapy for Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Blast Phase Chronic Myelogenous Leukemia (BP CML), and Mydelodysplastic Syndrome (MDS) Relapse After Allogeneic Transplantation - Full Text View - ClinicalTrials.gov
www.clinicaltrials.gov -
Safety and Tolerability Study of INNO-406 to Treat Chronic Myeloid Leukemia or Acute Lymphocytic Leukemia - Full Text View - ClinicalTrials.gov
www.clinicaltrials.gov -
A Study of Dasatinib vs. High-Dose Imatinib (600 mg) in Patients With Chronic Phase Chronic Myeloid Leukemia (CML) Who Failed to Achieve Complete Cytogenetic Response After 3-18 Months of Imatinib Therapy - Full Text View - ClinicalTrials.gov
www.clinicaltrials.gov -
Study of XL228 in Subjects With Chronic Myeloid Leukemia or Philadelphia-Chromosome-Positive Acute Lymphocytic Leukemia - Full Text View - ClinicalTrials.gov
www.clinicaltrials.gov -
 
MEDLINE
Tipifarnib and Bortezomib in Treating Patients With Acute Leukemia or Chronic Myelogenous Leukemia in Blast Phase - Full Text View - ClinicalTrials.gov
www.clinicaltrials.gov -
Detailed Description:. OBJECTIVES:. Primary. Determine the dose-limiting toxicity and maximum tolerated dose of tipifarnib and bortezomib in patients with relapsed or refractory acute myeloid leukemia, acute lymphoblastic leukemia, or chronic
Education Sessions for Young Relative Stem Cell Donors - Full Text View - ClinicalTrials.gov
www.clinicaltrials.gov -
adult acute myeloid leukemia in remission. atypical chronic myeloid leukemia, BCR-ABL1 negative. ... childhood acute myeloid leukemia in remission. childhood chronic myelogenous leukemia. chronic eosinophilic leukemia.
Analysis of Genetic Factors Related to Predisposition and Prognosis of Hematological Malignancies in Israel - Full Text View - ClinicalTrials.gov
www.clinicaltrials.gov -
Acute Myeloid Leukemia. Chronic Lymphocytic Leukemia. Chronic Myelogenous Leukemia. Study Type:. ... Leukemia, Myeloid, Acute. Leukemia, Myeloid. Leukemia, Myelogenous, Chronic, BCR-ABL Positive. Hematologic Neoplasms.
Evaluation of the Persistence of the Complete Molecular Remission After Stopping Imatinib Chronic Myeloid Leukemia - Full Text View - ClinicalTrials.gov
www.clinicaltrials.gov -
Evaluation of the Persistence of the Complete Molecular Remission After Stopping Imatinib Chronic Myeloid Leukemia ( STIM). ... Leukemia. Leukemia, Myeloid. Leukemia, Myelogenous, Chronic, BCR-ABL Positive. Chronic Disease. Neoplasms by Histologic Type.
Imatinib Standard Dose (400 mg/Day) Versus Imatinib High Dose (800 mg/Day) - Full Text View - ClinicalTrials.gov
www.clinicaltrials.gov -
serial number protocol ICSG/CML/022) in patients with Ph+ chronic myeloid leukemia ( CML) in chronic phase ( CP) previously untreated, at high Sokal risk. ... CML022. Additional relevant MeSH terms:. Leukemia. Leukemia, Myeloid. Leukemia, Myelogenous,

Result Pages: 1 2 3 4 5 6 Next




 
   SEARCH MEDICA RX
   Browse drugs by name:
A B C D E F G H I J
K L M N O P Q R S T
U V W X Y Z All      
   Search for drugs:
Search

 
 
FROM PHYSICIANS PRACTICE
'What They Should Really Teach in Medical School'
Julie Schopps, MD , February 6, 2012
The North Carolina-based pediatrician weighs in on why she thinks the real learning doesn't take place until students are out of the classroom.
Improve EHR Systems by Rethinking Medical Billing
Daniel Essin, MA, MD, February 6, 2012
Separating billing-related data from other clinical documentation and transmitting it to a billing system is not difficult …no matter how the charting is done.
Keeping Your Medical Practice’s Accounts Receivable on Track
P.J. Cloud-Moulds, February 4, 2012
Here are the minimum reports you should be running to keep an eye on your practices A/R.
Healthcare Providers Play Crucial Role in Helping Victims of Abuse
Stephen Hanson, PA-C , February 3, 2012
I would urge each and every one of you to be familiar with the warning signs of abuse, and the resources available to you all as healthcare providers.
Protecting Your Medical Practice's Data
Marisa Torrieri, February 3, 2012
Here's the scoop on how to implement a good data-backup plan at your office.
 
MOST POPULAR
 
COMMENTS